CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) was the recipient of unusually large options trading on Friday. Stock traders bought 8,896 call options on the stock. This is an increase of 262% compared to the typical volume of 2,457 call options.
Insider Buying and Selling
In other news, Director James Mulay sold 24,165 shares of CG Oncology stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $75.16, for a total value of $1,816,241.40. Following the transaction, the director owned 24,165 shares of the company’s stock, valued at $1,816,241.40. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Brian Guan-Chyun Liu acquired 371,085 shares of CG Oncology stock in a transaction that occurred on Thursday, June 25th. The shares were purchased at an average price of $66.87 per share, with a total value of $24,814,453.95. Following the purchase, the director owned 1,886,236 shares in the company, valued at $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 37,129 shares of company stock worth $2,663,817 in the last three months. 4.80% of the stock is owned by insiders.
Institutional Trading of CG Oncology
A number of institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC acquired a new stake in shares of CG Oncology in the first quarter valued at about $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of CG Oncology by 18.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock worth $876,000 after purchasing an additional 5,442 shares during the last quarter. Millennium Management LLC raised its position in shares of CG Oncology by 139.4% during the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock worth $14,597,000 after purchasing an additional 347,055 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in CG Oncology by 42.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock valued at $4,393,000 after buying an additional 53,461 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in CG Oncology by 12.3% in the 2nd quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock valued at $1,153,000 after buying an additional 4,847 shares in the last quarter. 26.56% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Read Our Latest Research Report on CG Oncology
CG Oncology Price Performance
CGON stock traded up $2.43 during midday trading on Friday, hitting $71.93. 436,258 shares of the stock traded hands, compared to its average volume of 1,193,355. CG Oncology has a 1-year low of $23.65 and a 1-year high of $77.00. The stock’s fifty day simple moving average is $65.23 and its 200-day simple moving average is $61.21. The firm has a market cap of $6.34 billion, a P/E ratio of -30.80 and a beta of 0.22.
CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The company had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. On average, research analysts predict that CG Oncology will post -2.89 earnings per share for the current year.
About CG Oncology
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Featured Stories
- Five stocks we like better than CG Oncology
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
- Sandisk: What the Chart Is Trying to Tell Us
- 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
